Hormone Replacement Therapy After Risk Reducing Salpingo-oophorectomy (NCT06972719)
Patient Centered Education About Hormone Replacement Therapy After Risk Reducing Salpingo-oophorectomy: a Pilot Randomized Controlled Trial
🩺 Plain-English Summary (8th-Grade Level)
The goal of this study is to develop an educational aid about hormone replacement therapy that physicians can share with patients as part of their pre-surgical counseling for a risk-reducing salpingo-oophorectomy (RRSO).
Who can join: Review the eligibility criteria below.
Location: UNC Chapel Hill Health System — Chapel Hill, North Carolina
Age range: 19 Years to 50 Years
🧪 Interventions in This Study
- Experimental Arm (BEHAVIORAL)
- SOC Arm (BEHAVIORAL)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (2 Sites)
- UNC Chapel Hill Health System — Chapel Hill, North Carolina
- Duke University Health System — Durham, North Carolina
📞 Contact the Study Coordinator
Phone: (919) 613-4584
Email: amelia.lorenzo@duke.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in BRCA1 Mutation
- BRCA Founder OutReach (BFOR) Study — Los Angeles, California
- BRCA1/2 Flu Vaccine — Philadelphia, Pennsylvania
- Studying the Effect of Denosumab on Preventing Breast Cancer in Women With a BRCA1 Germline Mutation — Los Angeles, California
- FaCT Trial (Facilitated Cascade Testing Trial) — New York, New York
- Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors — San Francisco, California
- An Intervention to Increase Genetic Testing in Families Who May Share a Gene Mutation Related to Cancer Risk and An Intervention to Help Patients and Their Primary Care Providers Stay Up-to-date About Uncertain Genetic Test Results — Basking Ridge, New Jersey
Explore by condition: All BRCA1 Mutation clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.